Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase 3 REFLECT Study
Published date:
06/09/2021
Excerpt:
407 patients were included in the serum analysis set (lenvatinib n=279, sorafenib n=128); 58 patients were included in the gene-expression analysis set (lenvatinib n=34, sorafenib n=24)….Higher baseline VEGF, ANG2, and FGF21 correlated with shorter OS in both treatment groups.